lopinavir has been researched along with HIV-Associated Lipodystrophy Syndrome in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (60.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prendergast, AJ | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Giralt, M; Gutierrez, Mdel M; Lamarca, K; Mateo, MG; Torres, F; Vidal, F; Villarroya, F; Villarroya, J | 1 |
| Téllez, MJ | 1 |
| Amin, J; Azwa, I; Belloso, WH; Boyd, MA; Chetchotisakd, P; Cooper, DA; Emery, S; Hoy, J; Kumarasamy, N; Lombaard, J; Mallon, PW; Mohapi, L; Molina, JM; Moore, CL; Phanuphak, P; Wood, R | 1 |
| Cahn, P; Carr, A; Chaves, R; Gatell, JM; Ritzhaupt, A; Workman, C; Zajdenverg, R; Zhang, W | 1 |
| Berzins, B; Evans, S; Forand, J; Hafner, R; Murphy, R; Owens, S; Shevitz, A; Tashima, K; Tebas, P; Yarasheski, K; Zhang, J | 1 |
| Belsey, E; Berzins, B; Chen, D; Choi, J; da Silva, B; Gerschenson, M; Kim, C; Libutti, DE; McComsey, GA; Murphy, RL; Shore, J; Taiwo, B; Weinstein, J | 1 |
| Butcher, DL; DiRienzo, AG; Garren, KW; Haas, DW; Haubrich, RH; Havlir, DV; Klingman, K; Komarow, L; Mellors, JW; Powderly, WG; Riddler, SA; Rooney, JF | 1 |
| Llenas-García, J; Pulido Ortega, F | 1 |
| Arribas López, JR | 1 |
| Alonso-Villaverde, C; Barrufet, P; Bonjoch, A; Clotet, B; Cucurull, J; Domingo, P; Estany, C; Force, L; Garrabou, G; Masabeu, A; Miró, O; Morén, C; Negredo, E; Pérez-Alvarez, N; Rodríguez-Santiago, B | 1 |
| Bloch, M; Calmy, A; Carr, A; Cooper, DA; Delhumeau, C; Finlayson, R; Hirschel, B; Norris, R; Rafferty, M; Wand, H | 1 |
| Bellón, JM; de José, MI; Gutiérrez, MD; Larru, B; Lorente, R; Micheloud, D; Muñoz-Fernández, MA; Palladino, C; Polo, R; Resino, S | 1 |
| Curto, J; del Rio, L; Domingo, P; Ferrer, E; Gatell, JM; Martínez, E; Negredo, E; Ordóñez, J; Podzamczer, D; Ribera, E; Rosales, J; Saumoy, M | 1 |
| Boué, F; Briot, K; Cohen-Codar, I; Delfraissy, JF; Flandre, P; Knysz, B; Kolta, S; Morlat, P; Norton, M; Pintado, C; Rode, R; Roux, C; Valantin, MA; Van, PN | 1 |
| Capeau, J; Danner, SA; Domingo, P; Feeney, ER; Mallon, PW; Reiss, P; van Agtmael, MA; van Vonderen, MG; Villarroya, F; Wit, F | 1 |
| Abrams, EJ; Arpadi, S; Coovadia, A; Kuhn, L; Martens, L; Patel, F; Shiau, S; Strehlau, R | 1 |
| Katzenstein, D | 1 |
| Gutiérrez, F; Hernández, I; Masiá, M; Navarro, A; Padilla, S | 1 |
| Burger, D; Clotet, B; Côté, H; López, S; Martínez, E; Miró, O; Moltó, J; Montaner, J; Negredo, E; Puig, J; Rey-Joly, C; Ribalta, J; Ruiz, L; Salazar, J | 1 |
| Mallal, S; Nolan, D; Reiss, P | 1 |
| Antoniadou, A; Giamarellou, H; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Poulakou, G; Tsiodras, S | 1 |
| Brizz, B; Collier, AC; Evans, S; Feinberg, J; Fischl, MA; Sattler, F; Shevitz, A; Shikuma, C; Tebas, P; Yarasheski, K; Zhang, J | 1 |
| Laurence, J | 1 |
| Ackermans, M; Blümer, RM; Danner, SA; Hassink, E; Reiss, P; Sauerwein, HP; Sutinen, J; van Agtmael, MA; van Vonderen, MG; Yki-Jarvinen, H | 1 |
4 review(s) available for lopinavir and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
[Lopinavir/ritonavir in human immunodeficiency virus-infected women].
Topics: Anti-HIV Agents; Body Size; Drug Combinations; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Meta-Analysis as Topic; Multicenter Studies as Topic; Patient Selection; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sex Characteristics | 2014 |
[Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cost Control; Developing Countries; Drug Combinations; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Multicenter Studies as Topic; Pilot Projects; Prospective Studies; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load; Viremia; Virus Replication | 2008 |
[The "induction-maintenance" strategy].
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Virus Replication; Zidovudine | 2008 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kidney Diseases; Lopinavir; Metabolic Syndrome; Nevirapine; Organophosphonates; Oxazines; Pyrimidinones; Risk Factors; Tenofovir | 2005 |
13 trial(s) available for lopinavir and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Gene Expression Regulation; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Organophosphonates; Ritonavir; Subcutaneous Fat; Tenofovir; Transcriptome | 2014 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-lin
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; CD4 Lymphocyte Count; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; International Cooperation; Lamivudine; Lopinavir; Male; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
Topics: Adiponectin; Adult; Body Composition; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Lopinavir; Male; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2008 |
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Intra-Abdominal Fat; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Radiography, Abdominal; Stavudine; Thigh; Viral Load; Zidovudine | 2009 |
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
Topics: Absorptiometry, Photon; Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lipid Metabolism; Lopinavir; Male; Pyrimidinones; Ritonavir | 2009 |
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; DNA, Mitochondrial; Drug Therapy, Combination; Electron Transport Complex IV; Extremities; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2009 |
No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
Topics: Absorptiometry, Photon; Adiposity; Adult; Anti-Retroviral Agents; Anticholesteremic Agents; Dideoxynucleosides; Drug Therapy, Combination; Extremities; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Pravastatin; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Uridine | 2010 |
Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Body Fat Distribution; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Atrophy; CD4 Lymphocyte Count; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; HIV Seropositivity; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Subcutaneous Fat; Treatment Outcome; Young Adult; Zidovudine | 2012 |
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
Topics: Anti-HIV Agents; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Infant; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Nevirapine; Ritonavir; South Africa; Stavudine | 2013 |
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; Drug Tolerance; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Lopinavir; Male; Middle Aged; Mitochondria; Nevirapine; Prospective Studies; Pyrimidinones; Ritonavir; Safety | 2005 |
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
Topics: Adiponectin; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Glucose; Glycerol; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperinsulinism; Insulin Resistance; Lamivudine; Lipid Metabolism; Lipids; Lopinavir; Male; Middle Aged; Pyrimidinones; Time Factors; Treatment Outcome; Zidovudine | 2008 |
8 other study(ies) available for lopinavir and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Complications of long-term antiretroviral therapy in HIV-infected children.
Topics: Anti-HIV Agents; Body Composition; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Lopinavir; Male; Nevirapine | 2013 |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Body Fat Distribution; CD4 Lymphocyte Count; Deoxyguanosine; F2-Isoprostanes; Glutathione; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Child; Child, Preschool; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Infant; Leptin; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir | 2010 |
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Body Fat Distribution; Body Mass Index; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Young Adult | 2011 |
The longer the better? Four years of durable, initially boosted protease treatment.
Topics: Antiretroviral Therapy, Highly Active; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Pyrimidinones; Ritonavir; Stavudine; Time Factors; Treatment Failure | 2004 |
Lipid abnormalities in HIV-Infected patients and lopinavir plasma concentrations.
Topics: Anti-HIV Agents; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperlipidemias; Lipids; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir | 2004 |
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oxazines; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides; Viral Load | 2006 |
Pivotal moments in HIV treatment: the 14th CROI.
Topics: Anti-Retroviral Agents; Clinical Trials as Topic; Congresses as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Maraviroc; Multicenter Studies as Topic; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles; United States | 2007 |